

# Thomas Decaens

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7625588/thomas-decaens-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75  
papers

4,576  
citations

26  
h-index

67  
g-index

91  
ext. papers

5,502  
ext. citations

5.7  
avg, IF

4.97  
L-index

#	Paper	IF	Citations
75	R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100445	10.3	0
74	GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma modulation of lysosomal functions. <i>Autophagy</i> , <b>2021</b> , 1-17	10.2	1
73	DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
72	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101590	2.4	2
71	Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. <i>British Journal of Cancer</i> , <b>2021</b> , 125, 190-199	8.7	6
70	Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	4
69	Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
68	First-in-human phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of oral GNS561, a palmitoyl-protein thioesterase 1 (PPT1) inhibitor, in patients with primary and secondary liver malignancies.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16175-e16175	2.2	2
67	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. <i>JHEP Reports</i> , <b>2021</b> , 3, 100285	10.3	1
66	International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria. <i>JHEP Reports</i> , <b>2021</b> , 3, 100331	10.3	4
65	GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer. <i>Journal of Cancer</i> , <b>2021</b> , 12, 5432-5438	4.5	1
64	Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	7
63	Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
62	Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
61	Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. <i>Livers</i> , <b>2021</b> , 1, 313-321		2
60	Immunomodulation for hepatocellular carcinoma therapy: current challenges.. <i>Current Opinion in Oncology</i> , <b>2021</b> , 34,	4.2	2
59	Hepatitis B virus exploits C-type lectin receptors to hijack cDC1s, cDC2s and pDCs. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1208	6.8	2

58	Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	10
57	Idarubicin doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 324-334	5.6	4
56	Reply to Comment on "Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges" 2019, , 1554. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
55	Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	9
54	GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF- $\beta$ inhibition. <i>Therapeutic Advances in Chronic Disease</i> , <b>2020</b> , 11, 2040622320942042	4.9	5
53	Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
52	Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment. <i>Cancers</i> , <b>2019</b> , 11,	6.6	24
51	Mammalian Target of Rapamycin Inhibitors, New Drugs for Beta-Catenin-Mutated Hepatocellular Carcinomas?. <i>Hepatology</i> , <b>2019</b> , 70, 1473-1476	11.2	
50	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , <b>2019</b> , 11,	6.6	41
49	A study of serum miRNA-122 in hepatitis C and associated hepatocellular carcinoma. <i>Vestnik Rossijskoi Akademii Meditsinskikh Nauk</i> , <b>2019</b> , 74, 388-395	0.4	
48	Circulating and Hepatic BDCA1+, BDCA2+, and BDCA3+ Dendritic Cells Are Differentially Subverted in Patients With Chronic HBV Infection. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 112	8.4	16
47	Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. <i>Clinical and Translational Gastroenterology</i> , <b>2019</b> , 10, e00058	4.2	21
46	Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 682-693	21.7	216
45	Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study. <i>Cancer</i> , <b>2018</b> , 124, 1964-1972	6.4	29
44	Macrotrabecular-massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , <b>2018</b> , 68, 103-112	11.2	83
43	Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 11145-11158	3.3	19
42	Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?. <i>Abdominal Radiology</i> , <b>2018</b> , 43, 1670-1681	3	7
41	Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1166-1172	13.4	128

40	Prediction of hepatocellular carcinoma recurrence after liver transplantation: Comparison of four explant-based prognostic models. <i>Liver International</i> , <b>2017</b> , 37, 717-726	7.9	16
39	Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2157-2165	6.1	16
38	Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis. <i>Liver International</i> , <b>2017</b> , 37, 1869-1876	7.9	13
37	Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels. <i>Mediators of Inflammation</i> , <b>2017</b> , 2017, 3214917	4.3	7
36	Hepatitis E Virus Infection after Platelet Transfusion in an Immunocompetent Trauma Patient. <i>Emerging Infectious Diseases</i> , <b>2017</b> , 23, 146-147	10.2	16
35	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. <i>European Journal of Cancer</i> , <b>2017</b> , 87, 101-112	7.5	38
34	Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. <i>Liver International</i> , <b>2016</b> , 36, 434-44	7.9	26
33	Functional imaging of hepatocellular carcinoma using diffusion-weighted MRI and (18)F-FDG PET/CT in patients on waiting-list for liver transplantation. <i>Cancer Imaging</i> , <b>2016</b> , 16, 4	5.6	19
32	Progression of fibrosis in patients with chronic viral hepatitis is associated with IL-17(+) neutrophils. <i>Liver International</i> , <b>2016</b> , 36, 1116-24	7.9	24
31	Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype. <i>Hepatology</i> , <b>2016</b> , 63, 1888-99	11.2	30
30	Performance of bile aspiration plus brushing to diagnose malignant biliary strictures during endoscopic retrograde cholangiopancreatography. <i>Endoscopy International Open</i> , <b>2016</b> , 4, E997-E1003	3	6
29	Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI. <i>Journal of Magnetic Resonance Imaging</i> , <b>2015</b> , 42, 1249-58	5.6	26
28	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. <i>Digestive and Liver Disease</i> , <b>2015</b> , 47, 869-76	3.3	34
27	Clinical trial watch: reports from the AASLD Liver Meeting, Boston, November 2014. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1196-203	13.4	18
26	Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1131-40	13.4	78
25	Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis?. <i>Journal of Magnetic Resonance Imaging</i> , <b>2014</b> , 39, 317-25	5.6	53
24	ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ $\beta$ -catenin pathway. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2014</b> , 464, 53-60	5.1	21
23	Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 855-65	13.4	202

22	Recurring multicystic inflammatory pseudotumor of the liver: a case report. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, e51-7	2.4	3
21	Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3517-24	2.2	568
20	Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3509-16	2.2	468
19	A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. <i>Gastroenterology</i> , <b>2013</b> , 145, 176-187	13.3	254
18	Recurrence after liver transplantation for hepatocellular carcinoma according to up-to-seven criteria. <i>Hepato-Gastroenterology</i> , <b>2013</b> , 60, 799-806		3
17	Liver transplantation for hepatocellular carcinoma: a model including $\alpha$ -fetoprotein improves the performance of Milan criteria. <i>Gastroenterology</i> , <b>2012</b> , 143, 986-94.e3; quiz e14-5	13.3	516
16	Liver transplantation for hepatocellular carcinoma: time for an international consensus. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2012</b> , 36, 316-8	2.4	6
15	Phase II study of sirolimus in treatment-naïve patients with advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 610-6	3.3	49
14	Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35 Suppl 1, S21-30	2.4	15
13	Liver magnetic resonance diffusion weighted imaging: 2011 update. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35, 539-48	2.4	11
12	Non-invasive diagnostic imaging of hepatocellular carcinoma: targeting cellular characterization?. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 224-6	13.4	1
11	Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. <i>Liver International</i> , <b>2011</b> , 31, 792-801	7.9	32
10	Transplantation for liver failure in patients with sickle cell disease: challenging but feasible. <i>Liver Transplantation</i> , <b>2011</b> , 17, 381-92	4.5	30
9	Outcomes in adult recipients of right-sided liver grafts in split-liver procedures. <i>Hpb</i> , <b>2010</b> , 12, 195-203	3.8	10
8	Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. <i>Annals of Surgery</i> , <b>2009</b> , 250, 738-46	7.8	211
7	Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. <i>Hepatology</i> , <b>2008</b> , 47, 247-58	11.2	112
6	Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. <i>Liver Transplantation</i> , <b>2007</b> , 13, 665-71	4.5	26
5	Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. <i>Liver Transplantation</i> , <b>2006</b> , 12, 1761-9	4.5	319

4	Apc tumor suppressor gene is the "zonation-keeper" of mouse liver. <i>Developmental Cell</i> , <b>2006</b> , 10, 759-770	0.2	378
3	Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 7319-25	5.6	50
2	Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. <i>Liver Transplantation</i> , <b>2005</b> , 11, 767-775	4.5	181
1	GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions		1